2021 EAU指南:非肌层浸润性膀胱癌(Ta,T1和CIS)

2021-09-09 欧洲泌尿外科学会 European Urology

本文提供了EAU关于非肌层浸润性膀胱癌诊治的最新指导建议,涉及分类、危险因素、诊断、预后因素以及治疗。

中文标题:

2021 EAU指南:非肌层浸润性膀胱癌(Ta,T1和CIS)

英文标题:

European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (Ta, T1, and Carcinoma in Situ)

发布机构:

欧洲泌尿外科学会

发布日期:

2021-09-09

简要介绍:

2021年9月,欧洲泌尿外科学会(EAU)更新了非肌层浸润性膀胱癌指南,膀胱癌分期为Ta、T1和原位癌(CIS)属于非肌层浸润性膀胱癌,本文提供了EAU关于非肌层浸润性膀胱癌诊治的最新指导建议,涉及分类、危险因素、诊断、预后因素以及治疗。

相关资料下载:
[AttachmentFileName(sort=1, fileName=2021 EAU指南:非肌层浸润性膀胱癌(Ta,T1和CIS).pdf)] GetToolGuiderByIdResponse(projectId=1, id=f20911c0021860b0, title=2021 EAU指南:非肌层浸润性膀胱癌(Ta,T1和CIS), enTitle=European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (Ta, T1, and Carcinoma in Situ), guiderFrom=European Urology, authorId=0, author=, summary=本文提供了EAU关于非肌层浸润性膀胱癌诊治的最新指导建议,涉及分类、危险因素、诊断、预后因素以及治疗。, cover=https://img.medsci.cn/2021914/1631623128914_5579292.jpg, journalId=0, articlesId=null, associationId=183, associationName=欧洲泌尿外科学会, associationIntro=成立于1973年,在欧洲泌尿外科的实践、研究、教育方面具有领导地位。已有超过16000名医疗人员加入其中。提供很多泌尿外科疾病的指南,更新较快。, copyright=0, guiderPublishedTime=Thu Sep 09 00:00:00 CST 2021, originalUrl=, linkOutUrl=, content=<p><span style="color: #373737;">2021年9月,欧洲泌尿外科学会(EAU)更新了非肌层浸润性膀胱癌指南,膀胱癌分期为Ta、T1和原位癌(CIS)属于非肌层浸润性膀胱癌,本文提供了EAU关于非肌层浸润性膀胱癌诊治的最新指导建议,涉及分类、危险因素、诊断、预后因素以及治疗。</span></p>, tagList=[TagDto(tagId=34797, tagName=非肌层浸润性膀胱癌)], categoryList=[CategoryDto(categoryId=5, categoryName=肿瘤科, tenant=100), CategoryDto(categoryId=26, categoryName=泌尿外科, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=34797, guiderKeyword=非肌层浸润性膀胱癌, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=指南, guiderLanguage=1, guiderRegion=2, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=5656, appHits=113, showAppHits=0, pcHits=1181, showPcHits=5543, likes=0, shares=13, comments=7, approvalStatus=1, publishedTime=Wed Sep 15 20:45:33 CST 2021, publishedTimeString=2021-09-09, pcVisible=1, appVisible=1, editorId=5579292, editor=FUNNYMAN, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=2, createdBy=null, createdName=FUNNYMAN, createdTime=Tue Sep 14 20:40:15 CST 2021, updatedBy=5579292, updatedName=FUNNYMAN, updatedTime=Sat Jan 06 21:59:18 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=2021 EAU指南:非肌层浸润性膀胱癌(Ta,T1和CIS).pdf)])
2021 EAU指南:非肌层浸润性膀胱癌(Ta,T1和CIS).pdf
下载请点击:
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1194503, encodeId=cca11194503ab, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230323/3e8445b84e0a4075bb263c6dc0e2c716/fc756ade7ac3433cac357aaec1a59def.jpg, createdBy=23bb6403664, createdName=ms3000001386273709, createdTime=Thu Feb 17 17:00:30 CST 2022, time=2022-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1080723, encodeId=332f1080e2304, content=很好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=526b6149654, createdName=ms5000001337597129, createdTime=Thu Dec 16 12:02:09 CST 2021, time=2021-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1054217, encodeId=9cbb105421e65, content=很好 已学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=4ff077255, createdName=huangliang, createdTime=Thu Sep 23 17:35:58 CST 2021, time=2021-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1053495, encodeId=1d8410534954e, content=很好,已学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e7821303550, createdName=zxcv002, createdTime=Tue Sep 21 14:13:51 CST 2021, time=2021-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1051965, encodeId=2b8c105196526, content=很受益, beContent=null, objectType=guider, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=989a5607928, createdName=ms2000001041372596, createdTime=Thu Sep 16 14:45:36 CST 2021, time=2021-09-16, status=1, ipAttribution=)]
    2022-02-17 ms3000001386273709

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1194503, encodeId=cca11194503ab, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230323/3e8445b84e0a4075bb263c6dc0e2c716/fc756ade7ac3433cac357aaec1a59def.jpg, createdBy=23bb6403664, createdName=ms3000001386273709, createdTime=Thu Feb 17 17:00:30 CST 2022, time=2022-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1080723, encodeId=332f1080e2304, content=很好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=526b6149654, createdName=ms5000001337597129, createdTime=Thu Dec 16 12:02:09 CST 2021, time=2021-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1054217, encodeId=9cbb105421e65, content=很好 已学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=4ff077255, createdName=huangliang, createdTime=Thu Sep 23 17:35:58 CST 2021, time=2021-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1053495, encodeId=1d8410534954e, content=很好,已学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e7821303550, createdName=zxcv002, createdTime=Tue Sep 21 14:13:51 CST 2021, time=2021-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1051965, encodeId=2b8c105196526, content=很受益, beContent=null, objectType=guider, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=989a5607928, createdName=ms2000001041372596, createdTime=Thu Sep 16 14:45:36 CST 2021, time=2021-09-16, status=1, ipAttribution=)]
    2021-12-16 ms5000001337597129

    很好

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1194503, encodeId=cca11194503ab, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230323/3e8445b84e0a4075bb263c6dc0e2c716/fc756ade7ac3433cac357aaec1a59def.jpg, createdBy=23bb6403664, createdName=ms3000001386273709, createdTime=Thu Feb 17 17:00:30 CST 2022, time=2022-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1080723, encodeId=332f1080e2304, content=很好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=526b6149654, createdName=ms5000001337597129, createdTime=Thu Dec 16 12:02:09 CST 2021, time=2021-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1054217, encodeId=9cbb105421e65, content=很好 已学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=4ff077255, createdName=huangliang, createdTime=Thu Sep 23 17:35:58 CST 2021, time=2021-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1053495, encodeId=1d8410534954e, content=很好,已学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e7821303550, createdName=zxcv002, createdTime=Tue Sep 21 14:13:51 CST 2021, time=2021-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1051965, encodeId=2b8c105196526, content=很受益, beContent=null, objectType=guider, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=989a5607928, createdName=ms2000001041372596, createdTime=Thu Sep 16 14:45:36 CST 2021, time=2021-09-16, status=1, ipAttribution=)]
    2021-09-23 huangliang

    很好 已学习

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1194503, encodeId=cca11194503ab, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230323/3e8445b84e0a4075bb263c6dc0e2c716/fc756ade7ac3433cac357aaec1a59def.jpg, createdBy=23bb6403664, createdName=ms3000001386273709, createdTime=Thu Feb 17 17:00:30 CST 2022, time=2022-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1080723, encodeId=332f1080e2304, content=很好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=526b6149654, createdName=ms5000001337597129, createdTime=Thu Dec 16 12:02:09 CST 2021, time=2021-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1054217, encodeId=9cbb105421e65, content=很好 已学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=4ff077255, createdName=huangliang, createdTime=Thu Sep 23 17:35:58 CST 2021, time=2021-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1053495, encodeId=1d8410534954e, content=很好,已学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e7821303550, createdName=zxcv002, createdTime=Tue Sep 21 14:13:51 CST 2021, time=2021-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1051965, encodeId=2b8c105196526, content=很受益, beContent=null, objectType=guider, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=989a5607928, createdName=ms2000001041372596, createdTime=Thu Sep 16 14:45:36 CST 2021, time=2021-09-16, status=1, ipAttribution=)]
    2021-09-21 zxcv002

    很好,已学习

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1194503, encodeId=cca11194503ab, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230323/3e8445b84e0a4075bb263c6dc0e2c716/fc756ade7ac3433cac357aaec1a59def.jpg, createdBy=23bb6403664, createdName=ms3000001386273709, createdTime=Thu Feb 17 17:00:30 CST 2022, time=2022-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1080723, encodeId=332f1080e2304, content=很好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=526b6149654, createdName=ms5000001337597129, createdTime=Thu Dec 16 12:02:09 CST 2021, time=2021-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1054217, encodeId=9cbb105421e65, content=很好 已学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=4ff077255, createdName=huangliang, createdTime=Thu Sep 23 17:35:58 CST 2021, time=2021-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1053495, encodeId=1d8410534954e, content=很好,已学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e7821303550, createdName=zxcv002, createdTime=Tue Sep 21 14:13:51 CST 2021, time=2021-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1051965, encodeId=2b8c105196526, content=很受益, beContent=null, objectType=guider, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=989a5607928, createdName=ms2000001041372596, createdTime=Thu Sep 16 14:45:36 CST 2021, time=2021-09-16, status=1, ipAttribution=)]
    2021-09-16 ms2000001041372596

    很受益

    0

拓展阅读

2016 AUA/SUO指南:非肌层浸润性膀胱癌的诊断和治疗

美国泌尿外科学会(AUA,American Urological Association) · 2016-04-01

2017 EAU指南:非肌层浸润性膀胱癌(Ta, T1, CIS)

欧洲泌尿外科学会(EAU,European Association of Urology) · 2017-03-01

非肌层浸润性膀胱癌二次电切中国专家共识

中华医学会泌尿外科学分会(CUA) · 2017-08-30

中国非肌层浸润性膀胱癌治疗与监测循证临床实践指南(2018简化版)

中国研究型医院学会(CRHA,Chinese Research Hospital Association) 泌尿外科专业委员会 · 2019-01-01

非肌层浸润性膀胱癌膀胱灌注治疗专家共识

中国泌尿外科相关专家组(统称) · 2019-01-30

中国非肌层浸润性膀胱癌治疗与监测循证临床实践指南(2018年标准版)

中国研究型医院学会(CRHA,Chinese Research Hospital Association) 泌尿外科专业委员会 · 2019-07-30